相关实验视频
Updated: Jun 6, 2025
09:09
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
1.6K
心血管医学中的SGLT2抑制剂:万能药还是潘多拉的盒子?
Stella de Aguiar Trigueirinho Ferreira1, Lucas Lentini Herling de Oliveira1, Arthur Cicupira Rodrigues de Assis1
1Department of Emergency, Instituto do Coração (InCor), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
British journal of hospital medicine (London, England : 2005)
|December 2, 2024
概括
-葡萄糖共运输体2抑制剂 (SGLT2i) 改善2型糖尿病患者的血糖和心血管健康. 本综述批判性地检查了评估SGLT2i心血管益处的关键临床试验的优点和局限性.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖共运输体2抑制剂 (SGLT2i) 是针对2型糖尿病 (T2DM) 的已知抗糖尿病药物.
- SGLT2 抑制剂在血糖控制之外提供了显著的心血管益处,减少了主要的心血管不良事件.
- 需要对研究这些心血管结果的关键试验中的局限性进行批判性评估.
研究的目的:
- 批判性地评估主要的随机临床试验,评估SGLT2抑制剂对心血管的影响.
- 为了突出这些关键试验的优势.
- 识别和讨论研究设计和结果报告中固有的局限性.
主要方法:
- 对SGLT2抑制剂和心血管结果的里程碑性随机临床试验的系统审查和批判性评估.
- 分析重点是试验设计,患者种群,结果测量和统计方法.
- 对报告中的心血管益处与潜在研究局限性的评估.
主要成果:
- 关键试验始终表明,随着SGLT2抑制剂的使用,主要不良心血管事件的显著减少.
- 优势包括大样本规模,长期随访和强大的心血管结果评估.
- 确定的局限性包括潜在的混因素,特定患者亚组分析和发现的概括性.
结论:
- SGLT2抑制剂在T2DM患者中提供了实质性的心血管保护,得到了强有力的试验数据的支持.
- 承认试验的局限性对于准确解释SGLT2抑制剂疗效和指导未来研究至关重要.
- 建议对特定患者子组和长期真实世界数据进行进一步调查.
相关概念视频
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159
01:27Glucose Transporters
22.5K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
172
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
172
01:32Secondary Active Transport
6.8K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
6.8K
01:23Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
01:17Oral Hypoglycemic Agents: Sulfonylureas
187
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
187